International Conference on Biomedical and Cancer Research
  • Follow

Accepted Abstracts

High Dose Rate Endobronchial Brachytherapy: As an effective palliative treatment modality in bronchial carcinoma

Jigna Bhattacharya*, R K Vyas, Saheli Saha 
Sterling Cancer Hospital, India 

Citation: Bhattacharya J, Vyas RK, Saha S (2019) High Dose Rate Endobronchial Brachytherapy: As an effective palliative treatment modality in bronchial carcinoma. SciTech Biomed-Cancer Sciences 2019. Tokyo: Japan

Received: August 05, 2019         Accepted: August 07, 2019         Published: August 07, 2019

Abstract

Background:
Treatment of inoperable carcinoma lung poses a challenge both due to the magnitude and local symptoms with resultant worsening of performance status of the patients. Endobronchial brachytherapy is an established modality for palliation of symptoms, namely dyspnoea, haemoptysis . This study was aimed at evaluating the role of HDR endobronchial brachytherapy with external radiotherapy for symptomatic improvement.
Method:
50 patients of inoperable Ca Lung with significant bronchial component, including non-small cell and small cell, were assessed. Patients were evaluated with fibre optic bronchoscopy regarding degree of bronchial obstruction. They were randomized into two treatment arms,
Arm A: Endobronchial brachytherapy (EBBT) followed by External RT.
Arm B: External beam Radiotherapy followed by endobronchial brachytherapy.
Endobronchial Brachytherapy was delivered using remote afterloading HDR brachytherapy with Ir192 source. Dose for external RT was 30Gy/10#, on Linear Accelerator or Co-60 teletherapy unit. Endobronchial brachytherapy dose range was 6.5Gy -10Gy in single or two fractions, one week apart. Bronchoscopic assessment was done after one week of each fraction of endobronchial brachytherapy as well as after completion of treatment at every 1 month for 3 months.  Response to the therapy was also assessed with the Speiser scoring criteria.
 
 
Results:
Total 50 patients were randomised into two arms . There were 20 patients in arm A and 30 patients in arm B. In short follow up, complete response for haemoptysis was achieved in 98% of patients (n=14), 80% patients showed complete response to dyspnoea (n=46). Symptoms like chest pain and cough showed less improvement after endobronchial brachytherapy. Re-expansion of atelectasis was seen in 100% patients (n=29). Values in both the arms were compared using Pearson Chi-square test. The pre- and post-treatment symptomatic differences were comparable in both the arms and statistically significant for dyspnoea, chest pain, cough, haemoptysis .
 
Conclusion:
Endobronchial brachytherapy, as documented, is an important palliative modality to relieve the obstructive symptoms like dyspnoea and hemoptysis, in patients with intrabronchial malignant mass.